Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Abstract

Background: Single nucleotide polymorphisms (SNPs) in DNA repair genes have a potential clinical value in predicting treatment outcomes. In the current study, we examined the association of SNPs in the genes XRCC1-rs25487, ERCC1-rs11615, ERCC2-rs238406, and ERCC2-rs13181 with colorectal cancer (CRC) risk, relapse-free survival (RFS), overall survival (OS), and toxicity during chemotherapy.Methods: SNPs were analysed in 590 CRC cases and 300 controls using TaqMan technology. The association of SNPs with CRC risk and toxicity during chemotherapy was analysed using Chi2 test. The Kaplan–Meier method and log-rank test was used to measure the effects of the SNPs on RFS and OS.Results: The CC genotype of ERCC2-rs238406 and the ERCC2-rs13181 C allele were associated with a significantly increased risk of CRC. The ERCC1-rs11615 genotype T/T was associated with stomatitis in adjuvant chemotherapy (p= 0.03). Also, more patients with the ERCC2-rs13181 C allele needed dose reduction compared to patients with the A/A genotype (p= 0.02). In first line chemotherapy, more patients with the ERCC1-rs11615 C allele suffered from nausea compared to those with the T/T genotype (p= 0.04) and eye reactions and thrombocytopenia were more common in patients with the ERCC2-rs13181 C allele compared to the A/A genotype (p= 0.006 and p= 0.004, respectively). ERCC2- rs238406 C/C was also associated with a higher frequency of thrombocytopenia (p= 0.03). A shorter 5-year OS was detected in stage I & II CRC patients with the ERCC2- rs238406 C allele (p= 0.02). However, there was no significant association between the SNPs and 5-year RFS.Conclusions: Both SNPs in ERCC2 were associated with risk of CRC as well as toxicity during first line treatment. In addition, ERCC2- rs238406 was linked to OS in early stage CRC. The ERCC1-rs11615 variant was associated with toxicity during adjuvant chemotherapy. The results add support to previous findings that SNPs in ERCC1 and ERCC2 have a prognostic and predictive value in clinical management of CRC.

Influence of Two DNA Repair Pathway Polymorphisms in Colorectal Cancer Risk in Southwest Iran

“…The outcomes of some investigation about the association of XRCC1 (rs25487) polymorphism with colorectal cancer risk have been contradictory. For example, two recent studies indicated association with increased risk of colorectal cancer (Karam et al, 2016;Abu Halim et al, 2016), while a case-control study in Sweden found no association with CRC risk (Salimzadeh et al, 2020). Also, other findings about the association of OGG1 (rs1052133) polymorphism with susceptibility to CRC remain controversial (Lai et al, 2016;Zou et al, 2016).…”

Epidemiological Evidence for Associations Between Genetic Variants and Osteosarcoma Susceptibility: A Meta-Analysis

“…The excision repair cross-complementation 3 (ERCC3) gene encodes a DNA helicase that plays an important role in nucleotide excision repair. The polymorphisms of ERCC3 have been reported to be associated with several cancers, such as colorectal cancer, pancreatic cancer, breast cancer, and OS (5,31,32). The potential mechanism of OS susceptibility was deemed to be its functions as rate-limiting enzymes in the NER pathway (33).…”